tiprankstipranks
Impel Pharmaceuticals (IMPLQ)
OTHER OTC:IMPLQ
US Market
Holding IMPLQ?
Track your performance easily

Impel Pharmaceuticals (IMPLQ) Income Statement

64 Followers

Impel Pharmaceuticals Income Statement

Last quarter (Q3 2023), Impel Pharmaceuticals's total revenue was $5.02M, an increase of 62.98% from the same quarter last year. In Q3, Impel Pharmaceuticals's net income was $-13.81M. See Impel Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 17.77M$ 12.65M$ 668.00K$ 0.00$ 0.00
Cost of Revenue
$ 2.30M$ 138.00K$ 691.00K$ 0.00-
Gross Profit
$ 11.04M$ 6.16M$ -23.00K$ 0.00-
Operating Expense
$ 39.08M$ 89.34M$ 71.46M$ 45.33M$ 41.57M
Operating Income
$ -70.11M$ -83.18M$ -71.49M$ -45.33M$ -41.57M
Net Non Operating Interest Income Expense
$ -9.61M$ -13.84M$ -4.24M$ -55.00K$ 417.00K
Other Income Expense
$ -9.69M$ 9.29M$ 805.00K$ -463.00K$ -680.00K
Pretax Income
$ -74.28M$ -106.31M$ -76.53M$ -45.80M$ -41.83M
Tax Provision
-$ -6.11M$ 2.00K$ 1.00K$ 30.00K
Earnings From Equity Interest Net Of Tax
-----
Net Income Common Stockholders
$ -74.28M$ -106.31M$ -76.41M$ -45.65M$ -42.36M
Basic EPS
$ -4.29$ -4.53$ -5.25$ -3.47$ -3.22
Diluted EPS
$ -3.12$ -4.53$ -5.25$ -3.47$ -3.22
Basic Average Shares
$ 94.69M$ 23.45M$ 14.60M$ 13.14M$ 13.14M
Diluted Average Shares
$ 94.69M$ 23.45M$ 14.60M$ 13.14M$ 13.14M
Dividend Per Share
-----
Total Operating Income As Reported
-----
Reported Normalized Basic E P S
-----
Reported Normalized Diluted E P S
-----
Rent Expense Supplemental
-----
Total Expenses
$ 41.38M$ 89.48M$ 72.15M$ 45.33M$ 41.57M
Net Income From Continuing And Discontinued Operation
$ -74.28M$ -106.31M$ -76.54M$ -45.80M$ -41.86M
Normalized Income
$ -16.73M$ -112.42M-$ -45.80M$ -41.86M
Interest Expense
-----
EBIT
$ -58.97M$ -92.48M$ -72.29M$ -45.33M$ -41.57M
EBITDA
$ -57.01M$ -90.47M$ -70.49M$ -44.26M$ -40.84M
Currency in USD

Impel Pharmaceuticals Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis